Aptevo Therapeutics Inc
$ 4.72
-7.09%
05 Jun - close price
- Market Cap 5,881,600 USD
- Current Price $ 4.72
- High / Low $ 5.03 / 4.71
- Stock P/E N/A
- Book Value 9.65
- EPS 1488.13
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.18 %
- ROE -5.18 %
- 52 Week High 92.34
- 52 Week Low 3.80
About
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company is headquartered in Seattle, Washington.
Analyst Target Price
$21.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-20 | 2025-11-06 | 2025-08-11 | 2025-05-15 | 2025-03-04 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-03-05 | 2023-11-14 | 2023-08-10 |
| Reported EPS | -6.41 | -5.9108 | -2.23 | -8.4 | -87.8 | -178.8 | -355.2 | -1.67 | -9.95 | -6.16 | -0.5 | -1.23 |
| Estimated EPS | -5.6 | -8.09 | -3.78 | -83.2 | -84.2 | -155 | -421.8 | -6.55 | -12.84 | -18.04 | -0.75 | -1.12 |
| Surprise | -0.81 | 2.1792 | 1.55 | 74.8 | -3.6 | -23.8 | 66.6 | 4.88 | 2.89 | 11.88 | 0.25 | -0.11 |
| Surprise Percentage | -14.4643% | 26.937% | 41.0053% | 89.9038% | -4.2755% | -15.3548% | 15.7895% | 74.5038% | 22.5078% | 65.8537% | 33.3333% | -9.8214% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: APVO
2026-05-29 06:40:02
Aptevo Therapeutics Inc. has appointed Mary J. Janatpour, Ph.D., as its Senior Vice President & Chief Scientific Officer. Dr. Janatpour brings over 25 years of oncology research and development leadership to the company, where she will lead research and preclinical development efforts. Her expertise will be crucial in advancing Aptevo's expanding pipeline of multipathway therapeutics and new radiopharmaceutical development strategy.
2026-05-28 20:39:48
The article announces that Aptevo Therapeutics has appointed Mary J. Janatpour, Ph.D., as their new Senior Vice President & Chief Scientific Officer. The content briefly mentions her title and the company she is joining. This is a standard corporate announcement regarding a leadership change.
2026-05-28 20:39:48
Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company, has appointed Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer. Dr. Janatpour brings over 25 years of oncology R&D leadership experience and will lead Aptevo's research and preclinical development efforts, supporting its expanding oncology pipeline including a new radiopharmaceutical therapeutic collaboration. Her expertise will be crucial in advancing the company's multispecific therapeutics and broader oncology strategy.
2026-05-28 13:14:00
Aptevo Therapeutics Inc. has appointed Mary J. Janatpour as Senior Vice President and Chief Scientific Officer, leveraging her 25 years of oncology research and development experience. She will lead the company's research and preclinical development for its multispecific therapeutics pipeline. This appointment comes as Aptevo advances its clinical candidate mipletamig and expands its preclinical strategy, including a radiopharmaceutical therapeutic collaboration with Niowave.
2026-05-28 12:09:36
Aptevo Therapeutics Inc. has appointed Mary J. Janatpour as Senior Vice President and Chief Scientific Officer, bringing over 25 years of oncology research and development experience to lead the company's preclinical efforts. This appointment comes as Aptevo faces financial challenges and focuses on its clinical candidate mipletamig and a new radiopharmaceutical therapeutic collaboration with Niowave. Despite a significant stock decline, the company maintains a strong balance sheet and positive clinical trial data for mipletamig.
2026-05-28 08:13:00
Aptevo Therapeutics Inc. has appointed Mary J. Janatpour as Senior Vice President and Chief Scientific Officer, leveraging her 25 years of oncology research and development experience. She will lead the company's research and preclinical development for multispecific therapeutics. This appointment coincides with Aptevo's focus on its clinical candidate mipletamig and a new radiopharmaceutical collaboration with Niowave, despite the company facing financial headwinds.
